NIKKEI 225
27,885.87 +65.47 (+0.24%) HANG SENG
19,441.18 -77.11 (-0.40%) CRUDE OIL
74.45 -2.48 (-3.22%) GOLD FUTURES
1,783.30 +2.00 (+0.11%) DOW
33,596.34 -350.76 (-1.03%) BTC-GBP
14,006.22 -42.17 (-0.30%)
Galapagos NV (GLPG.AS)
| Previous close | 37.60 |
| Open | 37.23 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 36.54 - 37.53 |
| 52-week range | 36.54 - 66.28 |
| Volume | |
| Avg. volume | 202,678 |
| Market cap | 2.399B |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.69 |
| Earnings date | 23 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 61.78 |
- Globe Newswire
Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors
Supportive outcome for Jyseleca as treatment option with a positive benefit/risk profile after review of safety data of all JAK inhibitors approved in Europe for treatment of inflammatory conditions This follows the recommended harmonization of EU labels for all JAK inhibitors by Pharmacovigilance Risk Assessment Committee (PRAC)For patients aged ≥65 years, current or long-time past smokers and patients with a history of atherosclerotic cardiovascular (CV) disease or other CV and malignancy risk
- Globe Newswire
Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022
Preliminary results from real-world FILOSOPHY, FILgotinib Observational Study Of Patient Health-related outcomes, in the first 200 patients with moderately to severely active rheumatoid arthritis (RA)Data showed that filgotinib induced rapid relief in pain and fatigue as early as Week 1 as well as improvements in disease activity1 at Month 17 additional presentations encompassing key analyses of filgotinib, including long term, integrated safety data and safety data in specific subpopulations, d
- Globe Newswire
Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
Guiding principles for a sustainable future: Invest in strategic therapeutic areas of oncology and immunologyRebuild and accelerate portfolio of transformational medicines in high unmet medical needsCombine internal with external innovation Capital allocation: Discontinue fibrosis and kidney disease to further invest in oncologyLeverage strong balance sheet through disciplined cash management and smart business development Oncology roadmap: Validate point-of-care CAR-T delivery model with proven
